BioPhorum comprises over 135 manufacturers and suppliers deploying their top 6,000 leaders and subject matter experts to work in nine focused Phorums, articulating the industry’s technology roadmap, defining the supply partner practices of the future, and developing and adopting best practices in drug substance, fill finish, process development and manufacturing IT.
BioPhorum deliverables are developed by teams of Subject Matter Experts (SME) from within and across Phorums, often building on and synthesizing existing practices to build best practice methodologies. In many instances SMEs from as many as twenty companies will contribute, challenge and test the assessments and practices before publications. Routinely papers undergo technical reviews from other technical experts within those member companies involved and names in a paper. As such BioPhorum papers are trusted by many companies in the industry and support industry wide adoption programs.
Within this context the adoption of peer reviewing of certain documents provides a final verification of quality and a way of formalizing feedback from respected parties not involved with the drafting process.
About peer review
Peer review is considered “to validate or authenticate scientific work, or guarantee its integrity” (Rennie 2003). It is the evaluation of a paper by identified reviewers, who make recommendations to the editor (in this case BioPhorum Communications Team) as to whether a paper should be accepted as is, revised prior to publication or rejected. We anticipate that as papers are tested at each stage from initiation onwards, rejection will be a rare event. Reviewers’ generally address quality, originality, and importance. They are also encouraged to make suggestions for improvement.
BioPhorum uses a single blind system of review. The names of the reviewers are hidden from the author. This is the traditional method of reviewing and is the most common type.